• 소규모 펩티드 합성 시스템
X
큐
주문하려면 연락
세균성 물

유리 (1) 30 ml 세균성 물
자격을 갖춘 주문이 있습니다$ 500 USD.
(캡슐 제품, 미용 펩티드, 프로모션 코드 및 배송 제외)

제품 사용 :이 제품은 연구 화학 물질로만 의도 된 것입니다.이 명칭은 시험 관내 시험 및 실험실 실험에만 연구 화학 물질을 엄격하게 사용할 수있게한다. 이 웹 사이트에서 제공되는 모든 제품 정보는 교육 목적으로 만 사용됩니다. 인간이나 동물에 어떤 종류의 신체적으로 소개되는 것은 법에 의해 엄격히 금지되어 있습니다. 이 제품은 라이센스가 부여 된 자격을 갖춘 전문가 만 처리해야합니다. 이 제품은 약물, 음식 또는 화장품이 아니며 약물, 음식 또는 화장품으로 잘못 브랜드화되거나 잘못 사용되거나 오해가되지 않을 수 있습니다.

위에

Ovagen은 난소 (양) 여포 자극 호르몬 (FSH)을 함유 한 유사하게 명명 된 Ovagen과 혼동해서는 안되는 트리 펩티드 바이오 레게 게이터입니다. 두 제품은 동일하지 않으며 완전히 다른 기능을 가지고 있습니다. FSH 유도체는 배란을 촉진하는 반면, 특히 다낭성 난소 증후군 (PCOS)과 같은 상태로 고통받는 여성에서 트립 펩티드는 간 기능 조절기입니다. 이 기사에서 Ovagen은 Tripeptide Bioregulator를 참조 할 것입니다.

Ovagen은 Vladimir Khavinson 박사에 의해 여러 다른 펩티드와 함께 개발 된 Khavinson 펩티드입니다. 다른 생물 분류기와 마찬가지로, Ovagen은 세포 및 핵막을 교차하여 DNA 구조 및 전사 패턴을 직접 조절할 수 있습니다. 또한, 대부분의 다른 생물 조절 펩티드와 마찬가지로, Ovagen은 조직-특이 적 효과를 갖는다. GLU-ASP-LEU 펩티드는 주로 간 및 소화관 기능을 조절하고 정상화하는 역할을하지만, HIV 바이러스의 생식을 제어하는데 유용 할 수도 있다는 증거가있다. 후자의 발견은 바이러스 수명주기를 이해하려는 HIV 연구자들에게 관심있는 Ovagen을 만들었습니다.

Ovagen 구조

아미노산 서열 :glu-asp-leu (edl)
분자식 :기음15시간25N3영형8분자량 : 375.37 g/mol
PubChem CID: 444128
Synonyms: EDL, glutamyl-aspartyl-leucine, SCHEMBL5329396, 1a30, CHEBI:137252

MoleculeSource: PubChem

Ovagen and the Liver

According to research from Dr. Khavinson, Ovagen is a bioregulator of the GI tract and liver. In the liver, it has been found to promote cell proliferation and prevent scarring and fibrotic changes that can lead to cirrhosis. In the GI tract, Ovagen helps to boost mucosal barrier function and reduces complications from antibiotic treatment, environmental insults, chemotherapy, malnutrition, and more.

Like most bioregulators, the most robust effects of Ovagen are seen in older individuals. The peptide appears to roll back DNA changes that occur with age, helping to reset the DNA in liver fibroblasts and GI mucosal cells to a more youthful state. In this more youthful state, the DNA is less condensed and therefore more genes are available for transcription. This results in a more functional cell that is less senescent and therefore “healthier.”

Research shows that Ovagen is well tolerate and may be useful in normalizing the function of the liver and GI tract in a number of different inflammatory and disease conditions. It may also be useful in the postoperative setting, during long-term antibiotic therapy, for overcoming the side effects of cancer treatments, and even as a diabetes preventative. Research on the GI and liver effects of Ovagen is ongoing.

Ovagen and HIV

The HIV-1 protease is an enzyme necessary for the HIV virus to survive. It functions to cleave newly synthesized proteins that make up the mature HIV virion. This infectious form of the HIV virus will not function without the HIV-1 protease. In other words, the enzyme is essential for the HIV virus to be able to infect more cells. Without the protease, the HIV virus produces non-infectious progeny and dies out. A number of HIV protease inhibitors are currently FDA approved and used in treatment. Unfortunately, the virus’s high mutation rate results in relatively rapid formation of resistance.

Research on Ovagen reveals that it is an effective HIV-1 protease inhibitor. In fact, it is one of the smallest and most potent protease inhibitors known with an effective concentration of just 50 microM. Unlike other protease inhibitors, Ovagen is highly soluble in water[1]. This latter fact makes it easier to administer.

Ovagen Summary

Ovagen is a tripeptide bioregulator with primary effects in the liver and GI tract. Though research on this Khavinson peptide is limited at this point, it has shown promise as a potential anti-aging peptide in the liver and GI tract. Ovagen reduces long-term fibrosis in the liver and helps to protect the GI mucosal layer from the effects of antibiotics, environmental toxins, and even chemotherapy. There is also interest in the ability of Ovagen to inhibit the replication of HIV.

Article Author

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Ovagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between

Peptide Gurus and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

Referenced Citations

  1. J. M. Louis, F. Dyda, N. T. Nashed, A. R. Kimmel, and D. R. Davies, “Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease,” Biochemistry, vol. 37, no. 8, pp. 2105–2110, Feb. 1998, doi: 10.1021/bi972059x.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.

Request Inquery

About us

PeptideGurus is a leading supplier of American-made research peptides, offering top-quality products at competitive prices. With a focus on excellence and customer service, they ensure a secure and convenient ordering process with global shipping.

Request a Quote

Peptide Gurus
  • Peptide Gurus
  • info@peptidegurus.com
  • Glendale, AZ, USA
  • © Copyright Peptide Gurus 2024. All rights reserved.
    All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration or HEALTH CANADA. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
    PeptideGurus is a chemical supplier. PeptideGurus is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Peptide Sciences is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

    CONTACT

    Request Inquery